Oncternal Therapeutics (ONCT) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ONCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCT, but not buy additional shares or sell existing shares.
View ONCT analyst ratings or view top-rated stocks.

6 brokers have issued 12 month target prices for Oncternal Therapeutics' shares. Their ONCT share price forecasts range from $1.30 to $9.00. On average, they predict the company's share price to reach $4.10 in the next twelve months. This suggests a possible upside of 1,266.7% from the stock's current price.
View analysts price targets for ONCT or view top-rated stocks among Wall Street analysts.

Oncternal Therapeutics' stock was trading at $1.00 at the beginning of the year. Since then, ONCT stock has decreased by 70.0% and is now trading at $0.30.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ONCT earnings forecast.

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02. The company earned $0.11 million during the quarter, compared to analysts' expectations of $0.21 million. Oncternal Therapeutics had a negative trailing twelve-month return on equity of 75.67% and a negative net margin of 4,985.85%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL), Aldeyra Therapeutics (ALDX), Boeing (BA), CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX).

Oncternal Therapeutics trades on the NASDAQ under the ticker symbol "ONCT."

Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ONCT stock can currently be purchased for approximately $0.30.

Oncternal Therapeutics (NASDAQ:ONCT) has a market capitalization of $17.69 million and generates $1.49 million in revenue each year. The company earns $-44,170,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

Oncternal Therapeutics' mailing address is 12230 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.oncternal.com. The company can be reached via phone at (858) 434-1113, via email at investor.relations@oncternal.com, or via fax at 901-844-8075.